Clinical Research Directory
Browse clinical research sites, groups, and studies.
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Sponsor: IDEAYA Biosciences
Summary
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2023-07-03
Completion Date
2030-04-30
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
Darovasertib
Oral, potent, selective inhibitor of Protein Kinase C
Locations (18)
HonorHealth Research Institute
Scottsdale, Arizona, United States
Moores Cancer Center
La Jolla, California, United States
Stanford Cancer Institute
Palo Alto, California, United States
University of Miami
Miami, Florida, United States
The Cancer and Hematology Centers
Grand Rapids, Michigan, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
Northwell
Manhasset, New York, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
St. Vincent's Health Sydney
Sydney, New South Wales, Australia
Alfred Health
Melbourne, Victoria, Australia
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Institute Curie
Paris, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Fondazione IRCCS Istituto Nazionale Tumori
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy
Leiden University Medical Center
Leiden, Netherlands